- Company
- K-pharma to participate in J.P. Morgan Healthcare Conference
- by Jan 8, 2024 06:09am
- Korean pharmaceutical and biotech firms are fully prepared to attend the J.P. Morgan Healthcare Conference, the first international event of the year. The spotlight is on what accomplishments Korean pharmaceutical and biotech firms might achieve at this event, where they will join global companies to discuss large-scale technology transfe
- Company
- LG Chem transfers its rare obesity drug rights for KRW 130B
- by Kim, Jin-Gu Jan 8, 2024 06:09am
- LG Chem announced on the 5th that it had licensed out its new drug candidate that targets a rare genetic disease characterized by severe appetite control dysfunction to the U.S-based Rhythm Pharmaceuticals. The agreement, which amounts to USD 350 million (KRW 400 billion), includes an upfront payment of USD 100 million (KRW 130 billion
- Company
- Trodelvy can be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Jan 8, 2024 06:09am
- Another new antibody-drug conjugate drug for breast cancer, ‘Trodelvy,’ can now be prescribed at general According to industry sources, Gilead Science Korea’s triple-negative breast cancer (TNBC) treatment ‘Trodelvy (sacituzumab govitecan-hziy)’ has recently passed the drug committee review of Seoul Asan Medical Center. In addit
- Company
- GMP issues causing delays in new drug approval
- by Eo, Yun-Ho Jan 8, 2024 06:08am
- The GMP process, which inspects the manufacturing facilities for pharmaceutical products, has been identified as a contributing factor to the delay in the approval of pharmaceuticals. The Ministry of Food and Drug Safety (MFDS) has acknowledged the issue, but they have not yet addressed alternative solutions. Consequently, the bottleneck
- Company
- Roche’s Lunsumio and Columvi win approval in Korea
- by Jan 5, 2024 05:41am
- Roche's Lunsumio and Columvi are the first bispecific antibodies for lymphoma treatment, showing effectiveness as a third-line treatment for patients with lymphoma. These two drugs are highly regarded for their clinical advantages, as they have additional specific antigen-binding sites compared to monoclonal antibodies. Roche Korea hel
- Company
- Pharma CEOs consider job cuts and reducing hiring in 2024
- by Kim, Jin-Gu Jan 5, 2024 05:41am
- 13% of pharmaceutical and bio company CEOs have announced plans to reduce employment this year. Apart from this, another 12% have indicated the possibility of reducing their workforce this year. Overall, the industry held a more cautious stance toward hiring this year. Compared to last year, the number of respondents who responded that
- Company
- Koselugo commences prescription with insurance coverage
- by Eo, Yun-Ho Jan 5, 2024 05:41am
- Hospitals have started prescribing Koselugo, a treatment for pediatric neurofibromatosis. AstraZeneca Korea’s Koselugo (ingredient: selumetinib), a neurofibromatosis, has recently passed the Drug Committee (DC) of tertiary hospitals, including Seoul National University Hospital, Samsung Seoul Hospital, Seoul St. Mary's Hospital, Seoul
- Company
- Celltrion to divest prescription drugs acquired from Takeda
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- The Celltrion group is selling divestiture of primary care business rights in the Asia-Pacific region acquired from Takeda Pharmaceutical in 2020. Among the business rights acquired from the previous deal, Celltrion group will initiate the sales of business rights for prescription drugs, excluding those intended for the domestic market
- Company
- Industry is less inclined to expand investment this year
- by Kim, Jin-Gu Jan 4, 2024 05:33am
- One in four CEOs of pharma and biotech companies announced that they will expand their investment in 2024. This is down by half compared to the response received in the survey last year when one in two CEOs said they would expand investment. This is likely a reflection of the growing economic uncertainty in Korea and abroad. 1 in
- Company
- New CKD drug Kerendia is expected to receive reimb soon
- by Eo, Yun-Ho Jan 4, 2024 05:33am
- New chronic kidney disease drug ‘Kerendia’ is expected to receive reimbursement status. According to the industry, Bayer has reached a settlement with National Health Insurance Service (NHIS) in negotiations for the reimbursement pricing of its drug Kerendia(finerenone), which is used to treat chronic kidney disease in patients with t
